A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia
E
Erik Imel, MD
Primary Investigator
Administratively Closed
18 years - 55 years
All
Phase
N/A
2 Locations
Brief description of study
To evaluate the effect of tildacerfont in reducing GC use in subjects with CAH
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Congenital Adrenal Hyperplasia
-
Age: 18 years - 55 years
-
Gender: All
Updated on
13 Nov 2025.
Study ID: ENDO-SPRUCE-SPR001-204, 2009967762, TX11428
